Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
42 pending office actions • 25 art units • 40 examiners • 0 of 42 (0%) have an AI response strategy ready • 23 patents granted in the last 365 days
H. Lee Moffitt Cancer Center and Research Institute Inc. has 42 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 40 distinct examiners and 25 distinct art units. This high number of art units reflects a very broad range of research and development within the biotechnology sector. With 42 pending office actions, the institute maintains a high volume of active prosecution, requiring significant coordination across many different technical groups at the USPTO.
LARA, CAROLINE MONSERRAT is the busiest examiner for the portfolio. This examiner is responsible for 2 pending office actions. With 40 distinct examiners managing 42 actions, the vast majority of the portfolio is being reviewed by different individuals across the 25 art units. This wide distribution means that no single examiner or art unit has a dominant influence over the institute's overall intellectual property strategy. Practitioners must manage 40 distinct examiner relationships, each with potentially different interpretations of the Biotechnology & Pharmaceuticals guidelines across the 25 art units.
Based on the USPTO statutory response window for each pending office action. 17 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 17 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (2%) |
| §101 + other | 8 (19%) |
| §103 only | 6 (14%) |
| §102 only | 1 (2%) |
| §112 only | 5 (12%) |
| Double-patenting only | 1 (2%) |
| Double-patenting + other | 6 (14%) |
| Multi-statute (no §101) | 14 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LARA, CAROLINE MONSERRAT | 2 | 100.0% | +0.0% |
| TURPIN, ZACHARY MARK | 2 | 4.0% | -5.0% |
| ROMERO, KRISTEN WANG | 1 | 68.8% | +31.9% |
| CHAO, ALLEN | 1 | 55.6% | +0.0% |
| MENDEZ MUNIZ, DYLAN JOHN | 1 | 79.2% | +27.8% |
| BRAM, STANLEY | 1 | 0.0% | +0.0% |
| ANDERSON, REBECCA L | 1 | 73.4% | +23.6% |
| DAUNER, JOSEPH G | 1 | 56.9% | +35.2% |
| FISHER, BRITTANY I | 1 | 84.5% | +12.3% |
| CORNET, JEAN P | 1 | 42.1% | +47.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18555584 | CULTURE OF TUMOR INFILTRATING LYMPHOCYTES FROM TUMOR DIGEST | LARA, CAROLINE MONSERRAT | 36d overdue |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17584547 | CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATORY DOMAINS | SINGH, ANOOP KUMAR | 59d overdue |
| 17622375 | A PEPTIDE-BASED SCREENING METHOD TO IDENTIFY NEOANTIGENS FOR USE WITH TUMOR INFILTRATING LYMPHOCYTES | JOHANSEN, PETER N. | 58d overdue |
| 18055956 | Bayesian Approach For Tumor Forecasting | RASNIC, HUNTER J | 44d overdue |
| 18030186 | HELICASE INHIBITORS FOR TREATMENT OF MEDICAL DISORDERS | LEE, HOI YAN NMN | 31d overdue |
| 17791706 | TAP63 REGULATED ONCOGENIC LONG NON-CODING RNAS | TURPIN, ZACHARY MARK | 31d overdue |
| 18842179 | CULTURE OF TUMOR INFILTRATING LYMPHOCYTES FROM TUMOR DIGEST | LARA, CAROLINE MONSERRAT | 30d overdue |
| 17636532 | DIAGNOSTICS AND METHODS FOR PROGNOSING RESPONSE TO IMMUNOTHERAPY BASED ON THE METHYLATION STATUS OF IMMUNE SYNAPSE GENE SIGNATURE | LEWIS, PATRICK T | 18d overdue |
| 17606489 | ARTIFICIAL ANTIGEN PRESENTING CELLS COMPRISING LIGANDS FOR NKG2D FOR EXPANDING IMMUNE CELLS FOR IMMUNOTHERAPY | ZHU, JIANJIAN | 5d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18668678 | ALLOSTERIC INHIBITOR OF WEE1 KINASE | ANDERSON, REBECCA L | 49d overdue |
| 18864708 | METHODS OF TREATING ULK3-ASSOCIATED CANCERS | ROMERO, KRISTEN WANG | — |
| 18772456 | METHODS AND SYSTEMS FOR INTEGRATING HIGH-THROUGHPUT CELLULAR PROFILES USING CELL CYCLE STATES | MENDEZ MUNIZ, DYLAN JOHN | — |
| 18709722 | METHYLATION SIGNATURES IN CELL-FREE DNA FOR TUMOR CLASSIFICATION AND EARLY DETECTION | DAUNER, JOSEPH G | — |
| 18704790 | METHODS FOR DIAGNOSING LEPTOMININGEAL METASTASIS | FISHER, BRITTANY I | — |
| 18697835 | INHIBITORS OF ULK1 AND METHODS OF USE | CORNET, JEAN P | — |
| Art Unit | Apps |
|---|---|
| 1638 | 3 |
| 1682 | 3 |
| 1633 | 2 |
| 1626 | 2 |
| 1622 | 2 |
| 1641 | 2 |
| 1631 | 2 |
| 1643 | 2 |
| 2675 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18864708 | METHODS OF TREATING ULK3-ASSOCIATED CANCERS | ROMERO, KRISTEN WANG | — | §112 | Non-Final OA | — | Pending | Nov 11, 2024 |
| 18844216 | PROCESSES FOR SYNTHESIS OF WITHANOLIDES AND WITHAFERINS AND ANALOGS THEREOF | CHAO, ALLEN | — | §102§103 | Non-Final OA | — | Pending | Sep 05, 2024 |
| 18842179 | CULTURE OF TUMOR INFILTRATING LYMPHOCYTES FROM TUMOR DIGEST | LARA, CAROLINE MONSERRAT | 1633 | §103§112 | Final Rejection | 30d overdue | Pending | Aug 28, 2024 |
| 18772456 | METHODS AND SYSTEMS FOR INTEGRATING HIGH-THROUGHPUT CELLULAR PROFILES USING CELL CYCLE STATES | MENDEZ MUNIZ, DYLAN JOHN | 2675 | §102§103 | Non-Final OA | — | Pending | Jul 15, 2024 |
| 18768434 | AURORA KINASE AND JANUS KINASE INHIBITORS FOR PREVENTION OF GRAFT VERSUS HOST DISEASE | BRAM, STANLEY | — | §103 | Non-Final OA | — | Pending | Jul 10, 2024 |
| 18668678 | ALLOSTERIC INHIBITOR OF WEE1 KINASE | ANDERSON, REBECCA L | 1626 | §102 | Final Rejection | 49d overdue | Pending | May 20, 2024 |
| 18709722 | METHYLATION SIGNATURES IN CELL-FREE DNA FOR TUMOR CLASSIFICATION AND EARLY DETECTION | DAUNER, JOSEPH G | — | §101§102§112 | Non-Final OA | — | Pending | May 13, 2024 |
| 18704790 | METHODS FOR DIAGNOSING LEPTOMININGEAL METASTASIS | FISHER, BRITTANY I | — | §102§103§112 | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18697835 | INHIBITORS OF ULK1 AND METHODS OF USE | CORNET, JEAN P | 1628 | §102§103§112 | Non-Final OA | — | Pending | Apr 02, 2024 |
| 18291999 | GENE SIGNATURE PREDICTING TERTIARY LYMPHOID STRUCTURES CONTAINING B CELLS | HAUK TEODORO, PRICILA NMN | 1645 | §101§103 | Final Rejection | — | Pending | Jan 25, 2024 |
| 18570899 | TRIAZINE INHIBITORS OF CYCLIN-DEPENDENT KINASES | HEASLEY, MEGHAN CHRISTINE | 1626 | §103 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18569178 | CANCER THERAPIES COMPRISING PEPTIDE LOADED CXCR3- AND CCR5-INDUCING DENDRITIC CELLS AND CHEMOKINE MODULATORY AGENTS | JACKSON III, WALTER | 1638 | §103 | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18565805 | CAR-T CELL THERAPY FOR TRIPLE NEGATIVE BREAST CANCER | LIU, SUE XU | — | §102§103§112Other | Non-Final OA | — | Pending | Nov 30, 2023 |
| 18563581 | IMMUNE CHECKPOINT INHIBITOR AND HDAC INHIBITOR COMBINATION THERAPY STRATEGY | AEDER, SEAN E | — | §112 | Final Rejection | — | Pending | Nov 22, 2023 |
| 18556744 | ENGINEERING BIOLOGICS TO HPV ONCOPROTEINS | CORNELIUS, CLAIRE ADRIENNE | 1672 | §112 | Non-Final OA | — | Pending | Oct 23, 2023 |
| 18556748 | DIAGNOSTIC TO SUPPORT CLINICAL TRIAL MATCHING AND EXPLORATORY BIOMARKER ANALYSES IN CANCER PATIENTS | SITTON, JEHANNE SOUAYA | 1682 | §101§102§112 | Non-Final OA | — | Pending | Oct 23, 2023 |
| 18556241 | SMALL-MOLECULE INHIBITORS FOR BETA-CATENIN/BCELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | ELENISTE, PIERRE PAUL | 1622 | §102§103§112 | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18555584 | CULTURE OF TUMOR INFILTRATING LYMPHOCYTES FROM TUMOR DIGEST | LARA, CAROLINE MONSERRAT | 1633 | §112DP | Final Rejection | 36d overdue | Pending | Oct 16, 2023 |
| 18554500 | A MULTIOMIC APPROACH TO MODELING OF GENE REGULATORY NETWORKS IN MULTIPLE MYELOMA | SAMALA, JAGADISHWAR RAO | 1618 | §102§103 | Non-Final OA | — | Pending | Oct 09, 2023 |
| 18277760 | TAP63 REGULATED ONCOGENIC LONG NON-CODING RNAS | KIM, YOUNG J | 1681 | §101§102§103§112DP | Non-Final OA | — | Pending | Aug 17, 2023 |
| 18274875 | NOVEL ESR1 DERIVED PEPTIDES AND USES THEREOF FOR NEOANTIGEN THERAPY | HUYNH, PHUONG N | 1641 | §101§102§112 | Non-Final OA | — | Pending | Jul 28, 2023 |
| 18253793 | INHIBITION OF KIR2DL2 FOR THE ENHANCEMENT OF ADOPTIVE IMMUNOTHERAPIES | MCLEOD, AFRICA MHAIRIE | 1635 | §101§112 | Non-Final OA | — | Pending | May 22, 2023 |
| 18030186 | HELICASE INHIBITORS FOR TREATMENT OF MEDICAL DISORDERS | LEE, HOI YAN NMN | 1693 | §101§102 | Non-Final OA | 31d overdue | Pending | Apr 04, 2023 |
| 18023261 | IMMUNE GENE SIGNATURES IN MUSCLE INVASIVE BLADDER CANCER | TURPIN, ZACHARY MARK | 1682 | DP | Final Rejection | — | Pending | Feb 24, 2023 |
| 18021845 | COMBINATION THERAPY COMPRISING HER-2-DC1 VACCINE AND A PROBIOTIC | BUTTICE, AUDREY L | 1647 | §103§112DP | Final Rejection | 119d overdue | Pending | Feb 17, 2023 |
| 18055956 | Bayesian Approach For Tumor Forecasting | RASNIC, HUNTER J | 3684 | §101 | Final Rejection | 44d overdue | Pending | Nov 16, 2022 |
| 17792661 | INHIBITION OF TAP63 REGULATED ONCOGENIC LONG NON-CODING RNAS (TROLLS) IN THE TREATMENT OF CANCER | HUDSON, AMY ROSE | 1636 | §103§112DP | Final Rejection | 72d overdue | Pending | Jul 13, 2022 |
| 17791706 | TAP63 REGULATED ONCOGENIC LONG NON-CODING RNAS | TURPIN, ZACHARY MARK | 1682 | §101§102§103§112 | Final Rejection | 31d overdue | Pending | Jul 08, 2022 |
| 17757475 | Systems and Methods for Producing Efficacious Regulatory T Cells | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103 | Non-Final OA | — | Pending | Jun 16, 2022 |
| 17782897 | CLINICAL DECISION SUPPORT FOR PERSONALIZED ADAPTIVE PROSTATE CANCER THERAPY | GROOMS, TIFFANY NICOLE | 1637 | §103§112 | Non-Final OA | 33d | Pending | Jun 06, 2022 |
| 17756138 | AKT INHIBITORS FOR ENHANCING CHIMERIC T CELL PERSISTENCE | VIVLEMORE, TRACY ANN | 1638 | §112 | Non-Final OA | 44d overdue | Pending | May 18, 2022 |
| 17642809 | HER3 PULSED DC1 THERAPY | VAN BUREN, LAUREN K | 1638 | §103DP | Final Rejection | 229d overdue | Pending | Mar 14, 2022 |
| 17685892 | HISTONE DEACETYLASE AS A MODULATOR OF PDLI EXPRESSION AND ACTIVITY | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | §112 | Non-Final OA | 117d overdue | Pending | Mar 03, 2022 |
| 17638363 | METHODS OF ENHANCING CAR T CELL THERAPY | BURKE, TIONNA M | 2178 | §103 | Final Rejection | — | Pending | Feb 25, 2022 |
| 17636532 | DIAGNOSTICS AND METHODS FOR PROGNOSING RESPONSE TO IMMUNOTHERAPY BASED ON THE METHYLATION STATUS OF IMMUNE SYNAPSE GENE SIGNATURE | LEWIS, PATRICK T | 1691 | §103§112 | Final Rejection | 18d overdue | Pending | Feb 18, 2022 |
| 17635119 | ANTI-CD83 CHIMERIC ANTIGEN RECEPTOR EXPRESSING T REGULATORY CELLS | LUNDE, GRACE HENRY | 1641 | §103§112DP | Non-Final OA | 184d overdue | Pending | Feb 14, 2022 |
| 17584547 | CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATORY DOMAINS | SINGH, ANOOP KUMAR | 1632 | §103§112 | Final Rejection | 59d overdue | Pending | Jan 26, 2022 |
| 17626315 | ENGINEERING NOTCH LIGANDS TO ENHANCE THE ANTI-TUMOR ACTIVITY OF ADOPTIVELY TRANSFERRED T CELLS | DENT, ALANA HARRIS | 1643 | §102§103DP | Final Rejection | — | Pending | Jan 11, 2022 |
| 17622375 | A PEPTIDE-BASED SCREENING METHOD TO IDENTIFY NEOANTIGENS FOR USE WITH TUMOR INFILTRATING LYMPHOCYTES | JOHANSEN, PETER N. | 1644 | §103§112 | Non-Final OA | 58d overdue | Pending | Dec 23, 2021 |
| 17614936 | THERAPEUTIC T-CELLS WITH MODIFIED EXPRESSION OF T-BET, EOMES, AND c-MYB TRANSCRIPTION FACTORS | CUNNINGCHEN, KATHLEEN MARY | 1646 | §103 | Non-Final OA | — | Pending | Nov 29, 2021 |
| 17606489 | ARTIFICIAL ANTIGEN PRESENTING CELLS COMPRISING LIGANDS FOR NKG2D FOR EXPANDING IMMUNE CELLS FOR IMMUNOTHERAPY | ZHU, JIANJIAN | 1631 | §102§103Other | Final Rejection | 5d overdue | Pending | Oct 26, 2021 |
| 17430331 | COMBINATION OF T-CELL THERAPY AND TARGETED THERAPY FOR TREATING THERAPY-RESISTANT MELANOMA WITH MUTATIONS IN THE BRAF GENE | FAUST, AMBER KATHLEEN | 1643 | §103§112 | Final Rejection | — | Pending | Aug 12, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial